**ABSTRACT**

Background: Pexiganan (PEX) is a 22-mer acidic synthetic analog of peptide magainin II that is currently in Phase 3 clinical trials as a topical antimicrobial (PEX cream 0.8% [8,000 µg/mL pexiganan free base]) for treatment of mild infections of diabetic foot ulcer (DFU).

Methods: Against PEX and comparator we tested laboratory strains as well as select pathogens from DFI surveillance Program designated as pathogens from DFI (2013). We also tested 10 non-DFI (305) and 200 clinical isolates from DFI (8 MRSA and 12 MSSA), the pexiganan MICs were either 16 or 32 µg/mL. The DFI surveillance Program designated as pathogens from DFI (2013) were 16 and 32 µg/mL, respectively.

Results: Surfaces of neutralization to pexiganan were published in the late 1980s by Ge et al. We therefore performed this study to determined both microbial microbicidal testing in isolation. PEX should be further evaluated as a topical antimicrobial therapy for DFU.

**MATERIALS AND METHODS**

**INTRODUCTION**

**RESULTS**

**DISCUSSION**

**REFERENCES**

**CONCLUSIONS**

**ACKNOWLEDGEMENT**